Monzr M. Al Malki, M.D. | City of Hope

Dr. Monzr M. Al Malki

Claim this profile

City of Hope Medical Center

Expert in Acute Myelogenous Leukemia
Expert in Myelodysplastic Syndrome
20 reported clinical trials
36 drugs studied

Area of expertise

1

Acute Myelogenous Leukemia

Global Leader

Monzr M. Al Malki has run 13 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:

HLA-A positive
HLA-A negative
HLA positive
2

Myelodysplastic Syndrome

Global Leader

Monzr M. Al Malki has run 11 trials for Myelodysplastic Syndrome. Some of their research focus areas include:

HLA-A positive
HLA-A negative
HLA positive

Affiliated Hospitals

Image of trial facility.

City Of Hope Medical Center

Image of trial facility.

City Of Hope

Clinical Trials Monzr M. Al Malki is currently running

Image of trial facility.

Music Therapy

for Anxiety in Blood Cancer Procedures

This phase III trial compares the effect of adding passive music when undergoing bone marrow biopsy/aspirate versus bone marrow biopsy/aspirate alone in reducing anxiety. Music therapy helps relieve pain or stress and promote well-being. Listening to music during a bone marrow biopsy/aspirate procedure may reduce anxiety during the procedure.

Recruiting

2 awards

Phase 3

5 criteria

Image of trial facility.

Vedolizumab + Cyclophosphamide + Tacrolimus

for Graft-versus-Host Disease

This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a donor. Giving reduced conditioning chemotherapy before an allogeneic HCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new stem cells to grow using less than standard doses of chemotherapy. Sometimes, the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Vedolizumab is a monoclonal antibody, which is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). It may reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus suppresses the immune system by preventing the activation of certain types of immune cells. Giving vedolizumab plus PTCy and short course tacrolimus may be effective at preventing GVHD after allogeneic HCT.

Recruiting

1 award

Phase 2

10 criteria

More about Monzr M. Al Malki

Clinical Trial Related

3 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 8 Active Clinical Trials

Treatments Monzr M. Al Malki has experience with

  • Cyclophosphamide
  • Tacrolimus
  • Fludarabine
  • Melphalan
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Mycophenolate Mofetil

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Monzr M. Al Malki specialize in?

Is Monzr M. Al Malki currently recruiting for clinical trials?

Are there any treatments that Monzr M. Al Malki has studied deeply?

What is the best way to schedule an appointment with Monzr M. Al Malki?

What is the office address of Monzr M. Al Malki?

Is there any support for travel costs?